Aspire Biopharma stockholders approve warrant share issuance proposal at special meeting

Aspire Biopharma Holdings shareholders approved key warrant adjustments at a special meeting on June 16, 2026. The proposals included authorizing the issuance of common stock upon warrant exercise above the 19.99% threshold at $0.00001 per share, adjusting the number of issuable shares under the financial advisor agreement, and voluntarily adjusting the warrants' exercise price.

Aspire Biopharma Holdings held a special shareholder meeting on June 16, 2026. * Shareholders authorized issuance of common stock upon exercise of warrants, including shares above the 19.99% threshold, at an exercise price of $0.00001 per share. * Investors also endorsed an adjustment to the number of common shares issuable upon exercise of the warrants under the warrant agreement with the company’s financial advisor. * Shareholders approved voluntary adjustments to the warrants’ exercise price under the terms of the warrant. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-029599), on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Aspire Biopharma Holdings held a special shareholder meeting on June 16, 2026. * Shareholders authorized issuance of common stock upon exercise of warrants, including shares above the 19.99% threshold, at an exercise price of $0.00001 per share. * Investors also endorsed an adjustment to the number of common shares issuable upon exercise of the warrants under the warrant agreement with the company’s financial advisor. * Shareholders approved voluntary adjustments to the warrants’ exercise price under the terms of the warrant. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-029599), on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here